Mesoblast Limited (NASDAQ:MESO) does about 584.46K shares in volume on a normal day but saw 25676365 shares change hands in Friday trading. The company now has a market cap of 1.41B USD and an enterprise value of about $1.45B. Its current market price is $17.88, marking an increase of 51.40% compared to the previous close of $11.81. The 52 week high reached by this stock is $20.57 whilst the lowest price level in 52 weeks is $3.12. The script in recent trading has seen the stock touch a high of $19.60 and a low of $16.25.

Mesoblast Limited (MESO) has a 20-day trading average at $13.80 and the current price is -13.08% off the 52-week high compared with 473.06% distance from its 52-week low. The 50-day simple moving average of the closing price is $12.98 and its 200-day simple moving average is $9.18. If we look at the stock’s price movements over the week, volatility stands at 13.11%, which decreases to 6.93% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.23 to suggest the stock is neutral.

7 analysts observing the Mesoblast Limited (MESO) stock have set the 12-month price targets for the company’s shares at between $7.53 and $23.00. The consensus objective for the share price is $18.05, suggesting that the stock has a potential upside of 0.94% over the period. The median price target is 14.86% away from the current levels at $21.00.

FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 14, 2020 when Maxim Group reiterated the stock to “Buy” and issued a price target of between $16 and $22. H.C. Wainwright resumed its price target at $6.50.

The current price level is 32.59%, 38.77%, and 96.11% away from its SMA20, SMA50, and SMA200 respectively, with the MESO price moving below the 50-day SMA on August 14. Mesoblast Limited (MESO) stock is up 15.35% over the week and 50.38% over the past month. Its price is 142.61% year-to-date and 250.59% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$0.14 above consensus estimates by $0.03. MESO’s earnings per share are forecast to grow by 29.70% this year and 51.60% over next year. Expected sales for next quarter are $64.14 million, which analysts say will come at $41.83 million for the current fiscal year and next year at $216.6 million. In addition, estimates put the company’s current quarterly revenue at an average of $12.71 million.

Its 12-month price target is $21.00. To reach the target analysts have set, the stock logically needs to grow 0.94 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7.53, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $23.00.

Outstanding shares total 107.53M with insiders holding 0.00% of the shares and institutional holders owning 2.10% of the company’s common stock. The company has a return on investment of -13.80% and return on equity of -13.60%. The beta has a value of 3.50. Price to book ratio is 3.94 and price to sales ratio is 42.36.

According to a U.S. Securities and Exchange Commission filing, M&G Investment Funds (3) OEIC – R has reduced its position in Mesoblast Limited (MESO) to 1,420,387 shares, mirroring a recent drop by 0.00%. M&G Investment Funds (3) OEIC – R dumped 0.0 shares of Mesoblast Limited common stock bringing its total worth to about $19.06 million at the end of recent close, SEC documents show. BNY Mellon Investment Fds – Mult cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.01% position in Mesoblast Limited thanks to 11788.0 shares amounting to $0.16 million.